Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xarelto rivaroxaban: Phase III data

In the double-blind Phase III RECORD1 trial in 3,153 evaluable patients, Xarelto reduced the relative risks of

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE